Q-omics provides the consensus-scored LUADT1 profile across patient tissues and cancer cell-line models. LUADT1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LUADT1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, LUADT1 RNA expression shows 5,720 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, HNSC, and STAD as cancer lineages where LUADT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LUADT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LUADT1 survival associations across molecular data types. LUADT1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LUADT1 RNA expression–survival associations across cancer types. High LUADT1 expression shows unfavorable associations in CHOL, CESC, BRCA, THCA and KICH, but favorable associations in BLCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for LUADT1 RNA expression.
This table summarizes LUADT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LUADT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LUADT1 shows higher tumor expression in HNSC, LUSC, LUAD and BRCA. The HNSC box plot shows higher LUADT1 RNA expression in tumor versus normal tissue (log2 FC = +0.082, t-test p = .014).
This table shows molecular features associated with LUADT1 in patient tissues and cancer cell lines. In patient samples, LUADT1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
